What's Happening?
KOMO Biosciences has announced the appointment of Darryl Sampey, PhD, to its Scientific Advisory Board. Dr. Sampey brings over two decades of experience in biologics development and manufacturing, with expertise in cell line and process development. As
the co-founder and CEO of BioFactura, Dr. Sampey has extensive experience in building and scaling biologics manufacturing capabilities. His appointment is expected to provide strategic guidance to KOMO Biosciences as it advances its precision genomic integration platforms. The company focuses on developing non-viral, large serine integrase-based platforms for genome modification, aiming to improve scalability and cost-effectiveness in biomanufacturing and therapeutic applications.
Why It's Important?
Dr. Sampey's appointment to KOMO Biosciences' Scientific Advisory Board is significant as it brings valuable expertise to the company's efforts in advancing genomic integration technologies. His experience in biologics manufacturing and process development is expected to enhance KOMO's strategic initiatives, potentially accelerating the development and commercialization of its platforms. This move underscores the importance of experienced leadership in driving innovation and competitiveness in the biotech industry. For KOMO Biosciences, leveraging Dr. Sampey's expertise could lead to improved operational efficiencies and expanded market opportunities, benefiting stakeholders and advancing the field of precision genome engineering.
